ALLMedicine™ Acute Myeloid Leukemia Center
Research & Reviews 24,393 results
https://doi.org/10.1038/s41588-021-00829-8 10.1038/ng0598-19 10.1056/NEJMra1510092 10.1038/nrc.2017.35 10.1146/annurev-genet-110711-155616 10.1038/35057062 10.1038/s41576-019-0165-8 10.1038/332164a0 10.1146/annurev-genom-082509-141802 10.1186/s13100-016-0065-9 10.1038/s41588-019-0562-0 10.1038/s41586-019-1913-9 10.1182/blood-2013-02-474833 10.1182/blood.2019003262 10.1038/nrc3343 10.1126/science.aam7304 10.1038/nbt.3235 10.1038/nature09209 10.1038/nature25179 10.1126/science.aaa7227 10.1016/j.celrep.2016.09.050 10.1002/bies.201500184 10.1038/nrd3674 10.1126/science.1247005 10.1126/science.7660125 10.1182/blood.V96.6.2108 10.1038/nature04980 10.1186/s13100-019-0192-1 10.1016/S0092-8674(00)81998-4 10.1093/nar/28.6.1418 10.2174/1568026043388358 10.1371/journal.pone.0001547 10.1186/1471-2091-12-18 10.1016/j.ccr.2012.03.003 10.1182/blood-2016-10-696054 10.5966/sctm.2012-0109 10.1182/blood-2015-11-683649 10.1038/nm.4125 10.1038/s41467-019-09745-2 10.1038/nm.4210 10.1016/j.ccell.2017.11.012 10.1016/j.celrep.2019.07.094 10.1158/2159-8290.CD-19-0152 10.1038/s41586-018-0750-6 10.1038/nmeth.3312 10.1038/nature14136 10.1073/pnas.0605300103 10.1016/j.gene.2010.02.005 10.1038/nature13483 10.1074/jbc.M701023200 10.1083/jcb.201302092 10.1038/nm.2661 10.1016/j.ccr.2012.03.014 10.1016/j.jmb.2006.01.089 10.1186/1475-2867-6-13 10.1038/nrm2147 10.1038/s41594-020-0372-1 10.1101/gad.266098.115 10.1101/gad.343186.120 10.1038/s41586-018-0784-9 10.1016/j.cmet.2019.02.014 10.1038/ni.3558 10.1146/annurev-immunol-042718-041356 10.1182/blood-2017-06-780882 10.1038/leu.2010.324 10.1016/j.stem.2018.01.011 10.1126/science.aan4673 10.1038/nprot.2017.153 10.1093/nar/gkz365 10.1016/j.cell.2013.12.001 10.1038/s41467-020-14362-5 10.1016/j.cell.2011.03.012 10.1186/s13059-014-0554-4 10.1093/bioinformatics/btp120 10.1093/bioinformatics/btt656 10.1186/s13059-014-0550-8 10.1073/pnas.0506580102 10.1016/j.cell.2017.08.003 10.1186/gb-2009-10-3-r25 10.1186/gb-2008-9-9-r137 10.1093/nar/gkw257
Nature Genetics; Gu Z, Liu Y et. al.
Apr 9th, 2021 - Transposable elements or transposons are major players in genetic variability and genome evolution. Aberrant activation of long interspersed element-1 (LINE-1 or L1) retrotransposons is common in human cancers, yet their tumor-type-specific functi...
https://doi.org/10.21037/apm-19-379
Annals of Palliative Medicine; Zhang X, Zhang X
Apr 9th, 2021 - Acute myeloid leukemia (AML) is a malignant clonal hematopoietic stem cell disease. Although there are many therapeutic options, it is still an incurable hematological malignancy. Moreover, the prognosis of AML is closely related to its cytogeneti...
https://doi.org/10.1016/j.blre.2021.100829
Blood Reviews; de Lima M, Roboz GJ et. al.
Apr 9th, 2021 - Relapse in acute myeloid leukemia (AML) is common, especially in older patients, and there is currently no standard of care maintenance therapy for those who achieve complete remission. Finding effective, tolerable maintenance therapy to prolong r...
https://doi.org/10.1158/1078-0432.CCR-20-4543
Clinical Cancer Research : an Official Journal of the Ame... Zhang H, Wang P et. al.
Apr 9th, 2021 - The survival rate of children with refractory/relapsed acute myeloid leukemia (R/R-AML) by salvage chemotherapy is minimal. Treatment with chimeric antigen receptor T cells (CAR-T) has emerged as a novel therapy to improve malignancies treatment. ...
https://doi.org/10.1007/s12032-021-01498-7 10.1111/j.1939-1676.1991.tb03135.x 10.1016/j.canlet.2014.12.047 10.1016/j.canlet.2015.07.009 10.1134/S0006297916020024 10.1186/s12943-017-0721-9 10.1016/S0733-8635(18)30190-6 10.11406/rinketsu.58.460 10.1182/blood.2019000813 10.1038/bcj.2016.50 10.1002/cncr.22233 10.1016/j.blre.2016.08.005 10.1056/NEJMra1406184 10.1586/ehm.10.30 10.4238/2015.February.2.15 10.1002/ijc.29563 10.1016/j.mehy.2018.03.007 10.1073/pnas.86.7.2369 10.1016/j.leukres.2019.106180 10.1111/cas.13170 10.1016/j.imlet.2010.08.002 10.1007/s00432-014-1674-7 10.1111/cas.12459 10.1016/j.humimm.2015.09.020 10.1038/mtm.2016.74 10.1111/bjh.15129 10.1016/j.canlet.2017.02.022 10.1016/j.cytogfr.2014.07.018 10.1089/jir.2017.0101 10.1158/1078-0432.CCR-18-0381 10.3390/ijms16011691 10.2174/0929867324666170712160621 10.1126/scitranslmed.aaf2341 10.3389/fimmu.2018.00658
Medical Oncology (Northwood, London, England); Kaser EC, Zhao L et. al.
Apr 9th, 2021 - Interleukins are signaling molecules involved in the immune system, and they play a variety of roles in different diseases and cancers. Acute myeloid leukemia (AML) is the most common type of leukemia in adults, and survival rate after diagnosis i...
Guidelines 95 results
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.
Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/
May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml
May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/
May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al
Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).
Drugs 59 results see all →
Clinicaltrials.gov 25,489 results
https://doi.org/10.1038/s41588-021-00829-8 10.1038/ng0598-19 10.1056/NEJMra1510092 10.1038/nrc.2017.35 10.1146/annurev-genet-110711-155616 10.1038/35057062 10.1038/s41576-019-0165-8 10.1038/332164a0 10.1146/annurev-genom-082509-141802 10.1186/s13100-016-0065-9 10.1038/s41588-019-0562-0 10.1038/s41586-019-1913-9 10.1182/blood-2013-02-474833 10.1182/blood.2019003262 10.1038/nrc3343 10.1126/science.aam7304 10.1038/nbt.3235 10.1038/nature09209 10.1038/nature25179 10.1126/science.aaa7227 10.1016/j.celrep.2016.09.050 10.1002/bies.201500184 10.1038/nrd3674 10.1126/science.1247005 10.1126/science.7660125 10.1182/blood.V96.6.2108 10.1038/nature04980 10.1186/s13100-019-0192-1 10.1016/S0092-8674(00)81998-4 10.1093/nar/28.6.1418 10.2174/1568026043388358 10.1371/journal.pone.0001547 10.1186/1471-2091-12-18 10.1016/j.ccr.2012.03.003 10.1182/blood-2016-10-696054 10.5966/sctm.2012-0109 10.1182/blood-2015-11-683649 10.1038/nm.4125 10.1038/s41467-019-09745-2 10.1038/nm.4210 10.1016/j.ccell.2017.11.012 10.1016/j.celrep.2019.07.094 10.1158/2159-8290.CD-19-0152 10.1038/s41586-018-0750-6 10.1038/nmeth.3312 10.1038/nature14136 10.1073/pnas.0605300103 10.1016/j.gene.2010.02.005 10.1038/nature13483 10.1074/jbc.M701023200 10.1083/jcb.201302092 10.1038/nm.2661 10.1016/j.ccr.2012.03.014 10.1016/j.jmb.2006.01.089 10.1186/1475-2867-6-13 10.1038/nrm2147 10.1038/s41594-020-0372-1 10.1101/gad.266098.115 10.1101/gad.343186.120 10.1038/s41586-018-0784-9 10.1016/j.cmet.2019.02.014 10.1038/ni.3558 10.1146/annurev-immunol-042718-041356 10.1182/blood-2017-06-780882 10.1038/leu.2010.324 10.1016/j.stem.2018.01.011 10.1126/science.aan4673 10.1038/nprot.2017.153 10.1093/nar/gkz365 10.1016/j.cell.2013.12.001 10.1038/s41467-020-14362-5 10.1016/j.cell.2011.03.012 10.1186/s13059-014-0554-4 10.1093/bioinformatics/btp120 10.1093/bioinformatics/btt656 10.1186/s13059-014-0550-8 10.1073/pnas.0506580102 10.1016/j.cell.2017.08.003 10.1186/gb-2009-10-3-r25 10.1186/gb-2008-9-9-r137 10.1093/nar/gkw257
Nature Genetics; Gu Z, Liu Y et. al.
Apr 9th, 2021 - Transposable elements or transposons are major players in genetic variability and genome evolution. Aberrant activation of long interspersed element-1 (LINE-1 or L1) retrotransposons is common in human cancers, yet their tumor-type-specific functi...
https://doi.org/10.21037/apm-19-379
Annals of Palliative Medicine; Zhang X, Zhang X
Apr 9th, 2021 - Acute myeloid leukemia (AML) is a malignant clonal hematopoietic stem cell disease. Although there are many therapeutic options, it is still an incurable hematological malignancy. Moreover, the prognosis of AML is closely related to its cytogeneti...
https://doi.org/10.1016/j.blre.2021.100829
Blood Reviews; de Lima M, Roboz GJ et. al.
Apr 9th, 2021 - Relapse in acute myeloid leukemia (AML) is common, especially in older patients, and there is currently no standard of care maintenance therapy for those who achieve complete remission. Finding effective, tolerable maintenance therapy to prolong r...
https://doi.org/10.1158/1078-0432.CCR-20-4543
Clinical Cancer Research : an Official Journal of the Ame... Zhang H, Wang P et. al.
Apr 9th, 2021 - The survival rate of children with refractory/relapsed acute myeloid leukemia (R/R-AML) by salvage chemotherapy is minimal. Treatment with chimeric antigen receptor T cells (CAR-T) has emerged as a novel therapy to improve malignancies treatment. ...
https://doi.org/10.1007/s12032-021-01498-7 10.1111/j.1939-1676.1991.tb03135.x 10.1016/j.canlet.2014.12.047 10.1016/j.canlet.2015.07.009 10.1134/S0006297916020024 10.1186/s12943-017-0721-9 10.1016/S0733-8635(18)30190-6 10.11406/rinketsu.58.460 10.1182/blood.2019000813 10.1038/bcj.2016.50 10.1002/cncr.22233 10.1016/j.blre.2016.08.005 10.1056/NEJMra1406184 10.1586/ehm.10.30 10.4238/2015.February.2.15 10.1002/ijc.29563 10.1016/j.mehy.2018.03.007 10.1073/pnas.86.7.2369 10.1016/j.leukres.2019.106180 10.1111/cas.13170 10.1016/j.imlet.2010.08.002 10.1007/s00432-014-1674-7 10.1111/cas.12459 10.1016/j.humimm.2015.09.020 10.1038/mtm.2016.74 10.1111/bjh.15129 10.1016/j.canlet.2017.02.022 10.1016/j.cytogfr.2014.07.018 10.1089/jir.2017.0101 10.1158/1078-0432.CCR-18-0381 10.3390/ijms16011691 10.2174/0929867324666170712160621 10.1126/scitranslmed.aaf2341 10.3389/fimmu.2018.00658
Medical Oncology (Northwood, London, England); Kaser EC, Zhao L et. al.
Apr 9th, 2021 - Interleukins are signaling molecules involved in the immune system, and they play a variety of roles in different diseases and cancers. Acute myeloid leukemia (AML) is the most common type of leukemia in adults, and survival rate after diagnosis i...
News 1,495 results
https://www.medscape.com/viewarticle/947261
Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...
https://www.medscape.com/viewarticle/946434
Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...
https://reference.medscape.com/viewarticle/943967
Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...
https://www.medscape.com/viewarticle/943743
Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate. PARP inhibitors are...
https://www.medscape.com/viewarticle/942309
Dec 8th, 2020 - Black race is the most important risk factor for patients with acute myeloid leukemia (AML) and is associated with poor survival, according to new findings. Among patients with AML younger than 60 years, the rate of overall 3-year survival was sig...
